Cargando…

VEGF -634C/G Genotype is Predictive of Long-term Survival after Treatment with a Definitive 5-Fluorouracil/cisplatin-based Chemoradiotherapy in Japanese Patients with Esophageal Squamous Cell Carcinoma

Background: Reports have been accumulating that genetic properties are predictive of clinical response after and/or toxicity during cancer chemotherapy, but little information is available concerning effects on long-term survival. In this study, 49 Japanese patients with esophageal squamous cell car...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamura, Takao, Kuwahara, Akiko, Yamamori, Motohiro, Nishiguchi, Kohshi, Nakamura, Tsutomu, Okuno, Tatsuya, Miki, Ikuya, Manabe, Yuki, Sakaeda, Toshiyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2012
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3498747/ https://www.ncbi.nlm.nih.gov/pubmed/23155356 http://dx.doi.org/10.7150/ijms.4914

Ejemplares similares

Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma
por: Kuwahara, Akiko, et al.
Publicado: (2011)

Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma
por: Kuwahara, Akiko, et al.
Publicado: (2009)

Genetic Polymorphisms in SLC23A2 as Predictive Biomarkers of Severe Acute Toxicities after Treatment with a Definitive 5-Fluorouracil/Cisplatin-Based Chemoradiotherapy in Japanese Patients with Esophageal Squamous Cell Carcinoma
por: Minegaki, Tetsuya, et al.
Publicado: (2014)

THRB Genetic Polymorphisms Can Predict Severe Myelotoxicity after Definitive Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma
por: Miki, Ikuya, et al.
Publicado: (2012)

Effects of Bolus Injection of 5-Fluorouracil on Steady-State Plasma Concentrations of 5-Fluorouracil in Japanese Patients with Advanced Colorectal Cancer
por: Tamura, Takao, et al.
Publicado: (2011)

Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma
por: Kuwahara, Akiko, et al.
Publicado: (2010)

TNF-α -857C>T Genotype is Predictive of Clinical Response after Treatment with Definitive 5-Fluorouracil/cisplatin-based Chemoradiotherapy in Japanese Patients with Esophageal Squamous Cell Carcinoma
por: Omatsu, Hideaki, et al.
Publicado: (2013)

TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma
por: Kuwahara, Akiko, et al.
Publicado: (2010)

Adverse Event Profiles of 5-Fluorouracil and Capecitabine: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
por: Kadoyama, Kaori, et al.
Publicado: (2011)

VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese
por: Yamamori, Motohiro, et al.
Publicado: (2008)

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS
por: Kadoyama, Kaori, et al.
Publicado: (2011)

Antipsychotics-Associated Serious Adverse Events in Children: An Analysis of the FAERS Database
por: Kimura, Goji, et al.
Publicado: (2015)

Serum Lactate Dehydrogenase Levels as a Predictive Marker of Oxaliplatin-Induced Hypersensitivity Reactions in Japanese Patients with Advanced Colorectal Cancer
por: Seki, Kyoko, et al.
Publicado: (2014)

Risk Factors for Oxaliplatin-Induced Hypersensitivity Reactions in Japanese Patients with Advanced Colorectal Cancer
por: Seki, Kyoko, et al.
Publicado: (2011)

Lower Body Mass Index is a Risk Factor for In-Hospital Mortality of Elderly Japanese Patients Treated with Ampicillin/sulbactam
por: Miura, Makoto, et al.
Publicado: (2016)

Aspirin- and Clopidogrel-associated Bleeding Complications: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS
por: Tamura, Takao, et al.
Publicado: (2012)

Omeprazole- and Esomeprazole-associated Hypomagnesaemia: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Tamura, Takao, et al.
Publicado: (2012)

The Novel Anticancer Drug KRN5500 Interacts with, but is Hardly Transported by, Human P‐Glycoprotein
por: Takara, Kohji, et al.
Publicado: (2000)

The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer
por: Guan, Xiaoxiang, et al.
Publicado: (2009)

Factors affecting the sensitivity of human-derived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin
por: MINEGAKI, TETSUYA, et al.
Publicado: (2013)

Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2013)

Association between VEGF-634G>C Gene Polymorphism with Gastric Premalignant Lesions and Serum VEGF Levels in Helicobacter pylori Gastritis Patients
por: Siregar, Gontar Alamsyah, et al.
Publicado: (2018)

Definitive chemoradiotherapy with low-dose continuous 5-fluorouracil reduces hematological toxicity without compromising survival in esophageal squamous cell carcinoma patients
por: Saito, Hirotake, et al.
Publicado: (2017)

Definitive Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil for Advanced Cervical Esophageal Cancer: A Medium-Term Outcome
por: Okamoto, Hiroshi, et al.
Publicado: (2022)

Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer
por: Steber, Cole, et al.
Publicado: (2021)

Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

SAT-634 The Effect of Continine Verified Smoking on the Development of Diabetes
por: Jung, Inha, et al.
Publicado: (2020)

Concurrent Chemoradiotherapy with Docetaxel, Cisplatin, and 5-fluorouracil Improves Survival of Patients with Advanced Esophageal Cancer Compared with Conventional Concurrent Chemoradiotherapy with Cisplatin and 5-fluorouracil
por: Tamaki, Yukihisa, et al.
Publicado: (2018)

VEGF as a Predictor for Response to Definitive Chemoradiotherapy and COX-2 as a Prognosticator for Survival in Esophageal Squamous Cell Carcinoma
por: Yoon, Mee Sun, et al.
Publicado: (2011)

Commonality of Drug-associated Adverse Events Detected by 4 Commonly Used Data Mining Algorithms
por: Sakaeda, Toshiyuki, et al.
Publicado: (2014)

PT634. Alleviation of neuropathic pain treated with opioid by electroconvulsive therapy
por: Iwata, Ken, et al.
Publicado: (2016)

Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer
por: Ueda, Hiroto, et al.
Publicado: (2017)

Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer
por: Kim, Yeon-Joo, et al.
Publicado: (2013)

Definitive Chemoradiotherapy for Advanced Pulmonary Sarcomatoid Carcinoma
por: Takeda, Kazuya, et al.
Publicado: (2016)

Structural mechanisms of the degenerate sequence recognition by Bse634I restriction endonuclease
por: Manakova, Elena, et al.
Publicado: (2012)

Therapeutic Potential of LNP-Mediated Delivery of miR-634 for Cancer Therapy
por: Gokita, Kentaro, et al.
Publicado: (2019)

Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634
por: Atrafi, Florence, et al.
Publicado: (2021)

Fitness, Food, and Biomarkers: Characterizing Body Composition in 19,634 Early Adolescents
por: Rodriguez, Alina, et al.
Publicado: (2022)

Phase II Trial of 5‐Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer
por: Ueda, Hiroto, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bq3d2klpie1i1q5je46c9d4hus